Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

The SURVIVE HERoes study: Targeting molecular relapse in breast cancer; trastuzumab deruxtecan versus standard-of-care treatment in ctDNA-positive HER2-positive/HER2-low early breast cancer

Trial in progress

ESMO Congress 2025